Purpose We report the case of a male neonate with a respiratory disorder who developed
adverse cardiorespiratory symptoms after the continuous infusion of midazolam. Methods To …

Purpose In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam
(OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently …

Background Midazolam, a benzodiazepine, is finding expanded use in neonatal intensive
care units. We studied the pharmacokinetics and metabolism of midazolam after a single …

What is known and objective Midazolam is a drug that is metabolized by cytochrome P450
(CYP450) enzymes, particularly CYP3A4 and CYP3A5. The presence of single‐nucleotide …

Background: In children, a large variability in pharmacokinetics of midazolam, a cytochrome
P450 3A4/5 (CYP3A4/5) enzyme substrate, has been described, which cannot be explained …

Aims To characterize the pharmacokinetics and metabolism of oral midazolam in 15 preterm
infants. Methods After an oral dose (0.1 mg kg− 1), blood was drawn up to 24 h after …

Midazolam is a drug that is metabolized by cytochrome P450 (CYP450) enzymes,
particularly CYP3A4 and CYP3A5. The present study aimed to determine the sex and age …

To predict first‐pass and systemic cytochrome P450 (CYP) 3A‐mediated metabolism of
midazolam in preterm neonates, a physiological population pharmacokinetic model was …

Midazolam is metabolized by the developmentally regulated intestinal and hepatic drug‐
metabolizing enzyme cytochrome P450 (CYP) 3A4/5. It is frequently administered orally to …

Background Although the pharmacokinetics of midazolam in critically ill children has been
described, there are no such reports in extracorporeal membrane oxygenation. Methods The …